Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
Yunkai Yang, Huan Zhang, Shanshan Huang, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 2, pp. 709-709
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Biological insights in non-small cell lung cancer
Rafael Rosell, Anisha Jain, Jordi Codony‐Servat, et al.
Cancer Biology and Medicine (2023), pp. 1-19
Open Access | Times Cited: 19
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Development of a new flippase-dependent mouse model for red fluorescence-based isolation of KRASG12D oncogene-expressing tumor cells
Dušan Hrčkulák, Jakub Onhajzer, Michaela Krausová, et al.
Transgenic Research (2025) Vol. 34, Iss. 1
Open Access
Copper-KRAS-COX2 Axis: A Therapeutic Vulnerability in Pancreatic Cancer
Joyeeta Roy, Rima Mouawad, Armita Kyani, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
Ramesh R. Kale, Charudatt Samant, Krishnadas Nandakumar, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151688-151688
Closed Access
Assessing the exercise‐related kinetics of circulating cell‐free DNA, circulating tumour DNA, DNase I activity and cytokines in patients with solid tumours: A pilot study
Elmo W. I. Neuberger, Alexandra Brahmer, Tobias Ehlert, et al.
Experimental Physiology (2025)
Open Access
Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathways
Hnin Ei Ei Khine, Utid Suriya, Thanyada Rungrotmongkol, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Clinical genomic profiling of malignant giant cell tumor of bone: A retrospective analysis using a real‑world database
Yusuke Tsuda, Koichi Okajima, Yuki Ishibashi, et al.
Medicine International (2024) Vol. 4, Iss. 2
Open Access | Times Cited: 3
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer
Jeremy B. Foote, Tyler Mattox, Adam B. Keeton, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
Cucurbitacin E Exerts Anti-Proliferative Activity via Promoting p62-Dependent Apoptosis in Human Non-Small-Cell Lung Cancer A549 Cells
Han‐Lin Hsu, Bo-Jyun Lin, Yu‐Chen Lin, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 10, pp. 8138-8151
Open Access | Times Cited: 7
Design, synthesis, and evaluation of purine and pyrimidine-based KRAS G12D inhibitors: Towards potential anticancer therapy
S.L. Park, Venu Venkatarame Gowda Saralamma, Sagar D. Nale, et al.
Heliyon (2024) Vol. 10, Iss. 7, pp. e28495-e28495
Open Access | Times Cited: 2
Mesonephric-like adenocarcinoma of the female genital tract: possible role of KRAS-targeted treatment—detailed molecular analysis of a case series and review of the literature for targetable somatic KRAS-mutations
Christine E. Brambs, Lars‐Christian Horn, Ruth Hiller, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 17, pp. 15727-15736
Open Access | Times Cited: 5
Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors
Prajna Tripathi, Rajni Kumari, Rajiv Pathak
International review of cell and molecular biology (2024), pp. 1-39
Closed Access | Times Cited: 1
Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma
Peng Lin, Wei Cheng, Xin Qi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1555-1555
Open Access | Times Cited: 1
Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis
Shoutao Dang, Shuyang Zhang, Jingyang Zhao, et al.
World Journal of Surgical Oncology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Pharmacogenetics in Oncology: A useful tool for individualizing drug therapy
Rita Nogueiras‐Álvarez, Inês Francisco
British Journal of Clinical Pharmacology (2024)
Closed Access | Times Cited: 1
Mechanistic Insights into the Roles of the IL-17/IL-17R Families in Pancreatic Cancer
Zhen Chen, Shuangying Qiao, Yang Liu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 17, pp. 13539-13539
Open Access | Times Cited: 3
Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors
Priyanka Sahu, Ankita Mitra, Anirban Ganguly
International review of cell and molecular biology (2024), pp. 167-222
Closed Access
Development of a new flippase-dependent mouse model for red fluorescence-based isolation of KrasG12Doncogene-expressing tumor cells
Dušan Hrčkulák, Michaela Krausová, Jakub Onhajzer, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The anti-cancer mechanism of Celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer
Kang Wu, Chentao Qiu, Qihong Ma, et al.
Toxicology and Applied Pharmacology (2024) Vol. 491, pp. 117077-117077
Closed Access
Non-invasive prediction of KRAS mutation in rectal cancer using hybrid intravoxel incoherent motion and diffusion kurtosis model
Jie Yuan, Ziyuan Wang, Wenli Tan, et al.
Research Square (Research Square) (2024)
Open Access
Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer types
Zahra Davoudi, Thomas S. Dexheimer, Nathan P. Coussens, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
ML‐Based Screening of miRNA Inhibitors and Intervention of lncRNA/miRNA/mRNA Axis in Oncogenic KRAS‐Associated Colorectal Cancer
Prasanna Srinivasan Ramalingam, Deepak B. Thimiri Govinda Raj, Murugan Subramanian, et al.
Advances in Public Health (2024) Vol. 2024, Iss. 1
Open Access
Exploring somatic mutations in BRAF, KRAS, and NRAS as therapeutic targets in Saudi colorectal cancer patients through massive parallel sequencing and variant classification
Thamer Abdulhamid Aljuhani, Noor Ahmad Shaik, Rahaf Talal Alqawas, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Page 1 - Next Page

Scroll to top